Boston, MA -- (ReleaseWire) -- 02/06/2014 -- Global Markets Direct's, 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Hospital Acquired Pneumonia (HAP) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
View Full Report Details and Table of Contents
- A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP).
- A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to Get This Report
- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned in this Report: AstraZeneca PLC, Cubist Pharmaceuticals, Inc., Basilea Pharmaceutica AG, Aridis Pharmaceuticals LLC, Tetraphase Pharmaceuticals Inc., Meiji Seika Pharma Co., Ltd., Biota Pharmaceuticals, Inc., Adenium Biotech ApS, Melinta Therapeutics Inc.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2013
- Community-Acquired Infections - Pipeline Review, H2 2013
- Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2013
- Pneumonia - Pipeline Review, H2 2013
- Bacterial Pneumonia - Pipeline Review, H2 2013
- Community Acquired Pneumonia - Pipeline Review, H2 2012
- Community Acquired Bacterial Pneumonia - Pipeline Review, H2 2012
- Staphylococcus Aureus Infections - Pipeline Review, H2 2013
- Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013
- Anthrax - Pipeline Review, H2 2013